CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma

Open access

Abstract

Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, is being evaluated in regimens containing CD20-targeted monoclonal antibodies (e.g. rituximab plus cylophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). To demonstrate combinability of epcoritamab with CD20 monoclonal antibodies (mAbs), potential interference of rituximab or obinutuzumab with epcoritamab was investigated. While there was dose-dependent binding interference between CD20 mAbs and epcoritamab through steric hindrance, ex vivo assays using tumor cell lines, R-CHOP-treated patient samples, and an animal model showed this did not impair tumor cell killing. In a pharmacokinetic model, >90% maximal cytotoxicity was predicted after the first full epcoritamab dose in the presence of therapeutic rituximab concentrations due to effective tumor-epcoritamab-T-cell trimer formation. Immunoprofiling of R-CHOP-treated DLBCL patient samples showed emergence of less-differentiated CD8 memory T cells, further supporting the feasibility of the combination in ongoing studies of epcoritamab with rituximab-containing chemoimmunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/10428194.2025.2504719

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 3

  1. Epkinly [package insert]. Plainsboro, NJ, USA: Genmab US, Inc; 2024.
  2. Tepkinly [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG; 2024.
  3. Epkinly [Japan package insert]. Minato-Ku, Tokyo, Japan: AbbVie GK, Genmab K.K; 2025.

Cited by

See all 5

Metadata

Authors
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., Li, T., Paauwe, M., Cosgrove, C., Chervin, A. S., Reilly, E. B., Epling-Burnette, P., & Szafer-Glusman, E.
Affiliations
  • AbbVie (United States) (US)
  • Genmab (United States) (US)
  • Genmab
  • AbbVie Inc
Venue
Leukemia & Lymphoma
Published
2025-06-18
Volume
66
Issue
9
Pages
1688-1699
ISSN
  • 1026-8022 (ISSN-L)
  • 1042-8194
  • 1029-2403
OpenAlex
W4411429251
Cited by
5
References
30
Citations by year
2026: 4 · 2025: 1
FWCI
3.30
Type
journal article
Language
en
Open access
Locations
  • Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
AbbVie
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
epcoritamab, CD3xCD20 bispecific antibody, T-cell engagers, rituximab, obinutuzumab, diffuse large B-cell lymphoma, follicular lymphoma, R-CHOP, steric hindrance, pharmacokinetic modeling, memory CD8+ T cells, combination therapy, relapsed/refractory lymphoma
MeSH terms
Rituximab, Antineoplastic Agents, Immunological, Animals, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Humans, Prednisone, T-Lymphocytes, Vincristine, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Antigens, CD20, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma. https://app.cochat.ai/papers/10.1080/10428194.2025.2504719
The paper
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., Li, T., Paauwe, M., Cosgrove, C., Chervin, A. S., Reilly, E. B., Epling-Burnette, P., & Szafer-Glusman, E. (2025). Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2025.2504719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.